Harvard Bioscience (HBIO) Acquisitions (2010 - 2018)

Harvard Bioscience's (HBIO) quarterly Acquisitions came in at $540000.0 in Q4 2018, down 9.24% quarter-over-quarter from $595000.0 in Q2 2018.

Analysis

Harvard Bioscience (HBIO) Acquisitions (2010 - 2018) Analysis & Trends

Harvard Bioscience (HBIO) has reported Acquisitions for 6 consecutive years, with $540000.0 the latest figure, recorded in Q4 2018.

On a quarterly basis, Acquisitions changed N/A year-over-year to $540000.0 in Q4 2018; TTM through Sep 2019 was $540000.0, a 99.21% decrease from a year earlier, with the FY2018 full-year figure at $68.5 million, changed N/A from the prior year.
Acquisitions was $540000.0 for Q4 2018 at Harvard Bioscience, down from $595000.0 in the prior quarter.
Over five years, Acquisitions peaked at $67.4 million in Q1 2018 and troughed at $540000.0 in Q4 2018.
A 3-year average of $17.1 million and a median of $4.5 million in 2015 frame the typical range for Acquisitions.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Thermo Fisher Scientific	224.11 Bn	220.05 Bn	8.34 Bn	-
2	Danaher	142.43 Bn	138.08 Bn	3.61 Bn	-
3	Agilent Technologies	40.29 Bn	38.54 Bn	1.04 Bn	950.00 Mn
4	Illumina	30.65 Bn	29.49 Bn	770.00 Mn	2.00 Mn
5	Revvity	13.60 Bn	12.58 Bn	416.87 Mn	-
6	Bio-Techne	11.27 Bn	11.00 Bn	211.39 Mn	-
7	Bio-Rad Laboratories	9.92 Bn	8.30 Bn	345.80 Mn	-
8	Repligen	9.19 Bn	8.18 Bn	110.04 Mn	-
9	10x Genomics	8.72 Bn	8.17 Bn	112.50 Mn	-
10	Harvard Bioscience	35.61 Mn	29.11 Mn	12.63 Mn	-

Historic Data

Download Data